TY - JOUR
T1 - IL15 modification enables CAR T cells to act as a dual targeting agent against tumor cells and myeloid-derived suppressor cells in GBM
AU - Zannikou, Markella
AU - Duffy, Joseph T.
AU - Levine, Rebecca N.
AU - Seblani, Maggie
AU - Liu, Qianli
AU - Presser, Aaron
AU - Arrieta, Victor A.
AU - Chen, Christopher J.
AU - Sonabend, Adam M.
AU - Horbinski, Craig M.
AU - Lee-Chang, Catalina
AU - Miska, Jason
AU - Lesniak, Maciej S.
AU - Gottschalk, Stephen
AU - Balyasnikova, Irina V.
N1 - Funding Information:
The study is supported by the National Institute of Neurological Disorders and Stroke R01NS106379 (IVB) and R01NS122395 (IVB) grants, and the Translational Bridge Award funded by the Robert H. Lurie Comprehensive Cancer Center (IVB). The authors thank the Flow Cytometry Core Facility, Mouse Histology and Phenotyping, and Pathology Core supported by National Cancer Institute grant P30-CA060553 awarded to the Robert H. Lurie Comprehensive Cancer Center. The authors are also grateful to patients donating their tissues for the data analysis through the Nervous System Tumor Bank, the Department of Neurosurgery, Northwestern University.
Publisher Copyright:
© 2023 BioMed Central Ltd.. All rights reserved.
PY - 2023/2/9
Y1 - 2023/2/9
N2 - Introduction The immunosuppressive tumor microenvironment (TME) is a major barrier to the efficacy of chimeric antigen receptor T cells (CAR-T cells) in glioblastoma (GBM). Transgenic expression of IL15 is one attractive strategy to modulate the TME. However, at present, it is unclear if IL15 could be used to directly target myeloid-derived suppressor cells (MDSCs), a major cellular component of the GBM TME. Here, we explored if MDSC express IL15Rα and the feasibility of exploiting its expression as an immunotherapeutic target. Methods RNA-seq, RT-qPCR, and flow cytometry were used to determine IL15Rα expression in paired peripheral and tumor-infiltrating immune cells of GBM patients and two syngeneic murine GBM models. We generated murine T cells expressing IL13Rα2-CARs and secretory IL15 (CAR.IL15s) or IL13Rα2-CARs in which IL15 was fused to the CAR to serve as an IL15Rα-targeting moiety (CAR.IL15f), and characterized their effector function in vitro and in syngeneic IL13Rα2+glioma models. Results IL15Rα was preferentially expressed in myeloid, B, and dendritic cells in patients' and syngeneic GBMs. In vitro, CAR.IL15s and CAR.IL15f T cells depleted MDSC and decreased their secretion of immunosuppressive molecules with CAR.IL15f T cells being more efficacious. Similarly, CAR.IL15f T cells significantly improved the survival of mice in two GBM models. TME analysis showed that treatment with CAR.IL15f T cells resulted in higher frequencies of CD8+T cells, NK, and B cells, but a decrease in CD11b+cells in tumors compared with therapy with CAR T cells. Conclusions We demonstrate that MDSC of the glioma TME express IL15Ra and that these cells can be targeted with secretory IL15 or an IL15Rα-targeting moiety incorporated into the CAR. Thus, IL15-modified CAR T cells act as a dual targeting agent against tumor cells and MDSC in GBM, warranting their future evaluation in early-phase clinical studies.
AB - Introduction The immunosuppressive tumor microenvironment (TME) is a major barrier to the efficacy of chimeric antigen receptor T cells (CAR-T cells) in glioblastoma (GBM). Transgenic expression of IL15 is one attractive strategy to modulate the TME. However, at present, it is unclear if IL15 could be used to directly target myeloid-derived suppressor cells (MDSCs), a major cellular component of the GBM TME. Here, we explored if MDSC express IL15Rα and the feasibility of exploiting its expression as an immunotherapeutic target. Methods RNA-seq, RT-qPCR, and flow cytometry were used to determine IL15Rα expression in paired peripheral and tumor-infiltrating immune cells of GBM patients and two syngeneic murine GBM models. We generated murine T cells expressing IL13Rα2-CARs and secretory IL15 (CAR.IL15s) or IL13Rα2-CARs in which IL15 was fused to the CAR to serve as an IL15Rα-targeting moiety (CAR.IL15f), and characterized their effector function in vitro and in syngeneic IL13Rα2+glioma models. Results IL15Rα was preferentially expressed in myeloid, B, and dendritic cells in patients' and syngeneic GBMs. In vitro, CAR.IL15s and CAR.IL15f T cells depleted MDSC and decreased their secretion of immunosuppressive molecules with CAR.IL15f T cells being more efficacious. Similarly, CAR.IL15f T cells significantly improved the survival of mice in two GBM models. TME analysis showed that treatment with CAR.IL15f T cells resulted in higher frequencies of CD8+T cells, NK, and B cells, but a decrease in CD11b+cells in tumors compared with therapy with CAR T cells. Conclusions We demonstrate that MDSC of the glioma TME express IL15Ra and that these cells can be targeted with secretory IL15 or an IL15Rα-targeting moiety incorporated into the CAR. Thus, IL15-modified CAR T cells act as a dual targeting agent against tumor cells and MDSC in GBM, warranting their future evaluation in early-phase clinical studies.
KW - Brain Neoplasms
KW - Cell Engineering
KW - Immunotherapy, Adoptive
KW - Myeloid-Derived Suppressor Cells
KW - T-Lymphocytes
UR - http://www.scopus.com/inward/record.url?scp=85147786538&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85147786538&partnerID=8YFLogxK
U2 - 10.1136/jitc-2022-006239
DO - 10.1136/jitc-2022-006239
M3 - Article
C2 - 36759014
AN - SCOPUS:85147786538
SN - 2051-1426
VL - 11
JO - Journal for ImmunoTherapy of Cancer
JF - Journal for ImmunoTherapy of Cancer
IS - 2
M1 - e006239
ER -